Yahoo Finance5d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti ...
PharmiWeb15d
Soliris (Eculizumab) Market Research Report Forecast to 2033
Market Research Report for 2025 delivers a comprehensive analysis of the industry's progress, examining both historical trends and the current market landscape. It provides key insights into ...
Nature4y
Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease: Collaborative Research and Licensing Opportunity
Recent off-label use of a complement inhibiting drug, eculizumab (CD55 inhibitor) was shown to provide a dramatic benefit in patients with CHAPLE disease with an immediate correction of ...
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...